Shanghai Runda Medical Technology Co., Ltd. (603108.SS)
CNY 18.05
(0.06%)
CNY 18.05
(0.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.84 Billion CNY | -6.98% |
| 2022 | 9.5 Billion CNY | 24.72% |
| 2021 | 7.62 Billion CNY | 25.07% |
| 2020 | 6.09 Billion CNY | 10.51% |
| 2019 | 5.51 Billion CNY | 25.03% |
| 2018 | 4.41 Billion CNY | 0.81% |
| 2017 | 4.37 Billion CNY | 132.09% |
| 2016 | 1.88 Billion CNY | 146.42% |
| 2015 | 765.26 Million CNY | 25.6% |
| 2014 | 609.26 Million CNY | 38.57% |
| 2013 | 439.69 Million CNY | 58.93% |
| 2012 | 276.66 Million CNY | 111.54% |
| 2011 | 130.78 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 8.85 Billion CNY | -1.44% |
| 2024 Q1 | 8.88 Billion CNY | 0.51% |
| 2024 Q2 | 8.98 Billion CNY | 1.07% |
| 2023 Q3 | 9.3 Billion CNY | -3.93% |
| 2023 Q2 | 9.68 Billion CNY | 1.13% |
| 2023 Q1 | 9.57 Billion CNY | 0.7% |
| 2023 FY | 8.84 Billion CNY | -6.98% |
| 2023 Q4 | 8.84 Billion CNY | -4.93% |
| 2022 Q4 | 9.5 Billion CNY | 3.23% |
| 2022 Q2 | 8.74 Billion CNY | 8.68% |
| 2022 FY | 9.5 Billion CNY | 24.72% |
| 2022 Q1 | 8.04 Billion CNY | 5.48% |
| 2022 Q3 | 9.21 Billion CNY | 5.39% |
| 2021 FY | 7.62 Billion CNY | 25.07% |
| 2021 Q1 | 6.75 Billion CNY | 10.86% |
| 2021 Q2 | 7.22 Billion CNY | 6.86% |
| 2021 Q3 | 7.76 Billion CNY | 7.53% |
| 2021 Q4 | 7.62 Billion CNY | -1.82% |
| 2020 Q4 | 6.09 Billion CNY | 3.52% |
| 2020 Q1 | 5.42 Billion CNY | -1.58% |
| 2020 Q2 | 6.12 Billion CNY | 12.73% |
| 2020 FY | 6.09 Billion CNY | 10.51% |
| 2020 Q3 | 5.88 Billion CNY | -3.78% |
| 2019 Q4 | 5.51 Billion CNY | 8.38% |
| 2019 Q2 | 4.8 Billion CNY | 1.53% |
| 2019 Q3 | 5.08 Billion CNY | 5.99% |
| 2019 FY | 5.51 Billion CNY | 25.03% |
| 2019 Q1 | 4.73 Billion CNY | 7.2% |
| 2018 Q2 | 4.72 Billion CNY | 0.68% |
| 2018 FY | 4.41 Billion CNY | 0.81% |
| 2018 Q4 | 4.41 Billion CNY | 0.42% |
| 2018 Q3 | 4.39 Billion CNY | -7.03% |
| 2018 Q1 | 4.69 Billion CNY | 7.25% |
| 2017 Q2 | 2.28 Billion CNY | 4.99% |
| 2017 FY | 4.37 Billion CNY | 132.09% |
| 2017 Q1 | 2.17 Billion CNY | 15.28% |
| 2017 Q4 | 4.37 Billion CNY | 11.67% |
| 2017 Q3 | 3.91 Billion CNY | 71.73% |
| 2016 Q1 | 949.19 Million CNY | 24.04% |
| 2016 Q4 | 1.88 Billion CNY | 17.33% |
| 2016 Q3 | 1.6 Billion CNY | 30.68% |
| 2016 Q2 | 1.22 Billion CNY | 29.57% |
| 2016 FY | 1.88 Billion CNY | 146.42% |
| 2015 FY | 765.26 Million CNY | 25.6% |
| 2015 Q1 | 673.42 Million CNY | 10.53% |
| 2015 Q2 | 725.34 Million CNY | 7.71% |
| 2015 Q3 | 668.19 Million CNY | -7.88% |
| 2015 Q4 | 765.26 Million CNY | 14.53% |
| 2014 FY | 609.26 Million CNY | 38.57% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q2 | 558.92 Million CNY | 0.0% |
| 2014 Q4 | 609.26 Million CNY | 0.0% |
| 2013 FY | 439.69 Million CNY | 58.93% |
| 2012 FY | 276.66 Million CNY | 111.54% |
| 2011 FY | 130.78 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Joinn Laboratories(China)Co.,Ltd. | 1.67 Billion CNY | -429.121% |
| WuXi AppTec Co., Ltd. | 17.66 Billion CNY | 49.939% |
| Autobio Diagnostics Co., Ltd. | 2.85 Billion CNY | -209.616% |
| Thalys Medical Technology Group Inc. | 2.02 Billion CNY | -336.337% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 3.19 Billion CNY | -176.81% |
| Chemclin Diagnostics Co., Ltd. | 431.76 Million CNY | -1948.576% |